Locations:
Search IconSearch
September 1, 2015/Cancer/Research

Reducing Antibiotic Delays For Febrile Cancer Patients in the ED

Protocol changes can improve outcomes

emergency_690x380

Fevers in cancer patients receiving chemotherapy can indicate an infection, which may be life- threatening. Quick administration of antibiotics is critical to minimize harm, shorten hospital stays and improve patient outcomes.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

With the goal of reducing antibiotic administration delays in these patients, Cleveland Clinic researchers worked with the medical center’s Emergency Department (ED) personnel to implement several changes, including:

  • Standardizing the definition of fever
  • Providing patients with cards alerting caregivers to the severity of febrile neutropenia (FN)
  • Revising ED triage levels to elevate FN to the level of heart attack or stroke
  • Standardizing the FN treatment protocol in the electronic medical record
  • Ensuring immediate antibiotic availability in the ED

The researchers then studied all adult cancer patients who presented with fever at Cleveland Clinic’s ED between June 2012 and June 2013, comparing their outcomes with those of a group of cancer patients treated in the ED prior to the FN changes, and to a group of febrile cancer patients admitted directly to the hospital’s inpatient oncology service.

The investigators followed participating cancer patients for one year. Results showed that the FN protocol changes significantly decreased the time it took affected patients to receive antibiotics and shortened their hospital stays compared with the other groups.

Read an account of the research in the ASCO Post.

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024/Cancer/Research
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024/Cancer/Research
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023/Cancer/Research
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

Ad